TP53 and head and neck squamous cell carcinoma: In conclusion, we identified ATO as potentially valuable drug for treatment of p53-deficient SCCHN, recommending its further evaluation for HPV-negative SCCHN given the high frequency of TP53 loss-of-function mutations in this patient subset.